Search

Your search keyword '"Magnes, Teresa"' showing total 29 results
Start Over Author "Magnes, Teresa"
29 results on '"Magnes, Teresa"'

2. Clonal evolution and heterogeneity in metastatic head and neck cancer—An analysis of the Austrian Study Group of Medical Tumour Therapy study group

Author

Melchardt, Thomas, Magnes, Teresa, Hufnagl, Clemens, Thorner, Aaron R., Ducar, Matthew, Neureiter, Daniel, Tränkenschuh, Wolfgang, Klieser, Eckhard, Gaggl, Alexander, Rösch, Sebastian, Rasp, Gerd, Hartmann, Tanja N., Pleyer, Lisa, Rinnerthaler, Gabriel, Weiss, Lukas, Greil, Richard, and Egle, Alexander

Published
2018
Full Text
View/download PDF

5. Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer

Author

WAGNER, SANDRO M., primary, MAGNES, TERESA, additional, MELCHARDT, THOMAS, additional, KIEM, DOMINIK, additional, WEISS, LUKAS, additional, NEUREITER, DANIEL, additional, WAGNER, CHRISTINA, additional, ARETIN, MARIE-BERNADETTE, additional, NEMEC, STEFAN, additional, GAMERITH, GABRIELE, additional, PALL, GEORG, additional, GREIL, RICHARD, additional, and FUEREDER, THORSTEN, additional

Published
2023
Full Text
View/download PDF

11. Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies

Author

Magnes, Teresa, primary, Wagner, Sandro, additional, Thorner, Aaron R., additional, Neureiter, Daniel, additional, Klieser, Eckhard, additional, Rinnerthaler, Gabriel, additional, Weiss, Lukas, additional, Huemer, Florian, additional, Schlick, Konstantin, additional, Zaborsky, Nadja, additional, Steiner, Markus, additional, Greil, Richard, additional, Egle, Alexander, additional, and Melchardt, Thomas, additional

Published
2021
Full Text
View/download PDF

12. Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients

Author

Schlick, Konstantin, primary, Hohla, Florian, additional, Hamacher, Frank, additional, Hackl, Hubert, additional, Hufnagl, Clemens, additional, Markus, Steiner, additional, Magnes, Teresa, additional, Gampenrieder, Simon Peter, additional, Melchardt, Thomas, additional, Stättner, Stefan, additional, Hauser-Kronberger, Cornelia, additional, Greil, Richard, additional, and Rinnerthaler, Gabriel, additional

Published
2021
Full Text
View/download PDF

13. Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial

Author

Rinnerthaler, Gabriel, primary, Gampenrieder, Simon Peter, additional, Hackl, Hubert, additional, Steiner, Markus, additional, Monzo-Fuentes, Claudia, additional, Melchardt, Thomas, additional, Magnes, Teresa, additional, Huemer, Florian, additional, Westphal, Theresa, additional, Hufnagl, Clemens, additional, Hauser-Kronberger, Cornelia, additional, Egle, Alexander, additional, and Greil, Richard, additional

Published
2020
Full Text
View/download PDF

14. Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30‐positive aggressive lymphomas

Author

Wagner, Sandro M., primary, Melchardt, Thomas, additional, Egle, Alexander, additional, Magnes, Teresa, additional, Skrabs, Cathrin, additional, Staber, Philipp, additional, Simonitsch‐Klupp, Ingrid, additional, Panny, Michael, additional, Lehner, Barbara, additional, Greil, Richard, additional, Keil, Felix, additional, Jäger, Ulrich, additional, and Sillaber, Christian, additional

Published
2020
Full Text
View/download PDF

15. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL‐8a mabtenance trial

Author

Egle, Alexander, primary, Melchardt, Thomas, additional, Obrtlíková, Petra, additional, Smolej, Lukáš, additional, Kozák, Tomáš, additional, Steurer, Michael, additional, Andel, Johannes, additional, Burgstaller, Sonja, additional, Mikušková, Eva, additional, Gercheva, Liana, additional, Nösslinger, Thomas, additional, Papajík, Tomáš, additional, Ladická, Miriam, additional, Girschikofsky, Michael, additional, Hrubiško, Mikuláš, additional, Jäger, Ulrich, additional, Voskova, Daniela, additional, Pecherstorfer, Martin, additional, Králiková, Eva, additional, Burcoveanu, Christina, additional, Spasov, Emil, additional, Petzer, Andreas, additional, Mihaylov, Georgi, additional, Raynov, Julian, additional, Oexle, Horst, additional, Zabernigg, August, additional, Flochová, Emília, additional, Palášthy, Stanislav, additional, Stehlíková, Olga, additional, Doubek, Michael, additional, Altenhofer, Petra, additional, Weiss, Lukas, additional, Magnes, Teresa, additional, Pleyer, Lisa, additional, Klingler, Anton, additional, Mayer, Jiří, additional, and Greil, Richard, additional

Published
2019
Full Text
View/download PDF

16. Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM

Author

Huemer, Florian, primary, Melchardt, Thomas, additional, Jansko, Bettina, additional, Wahida, Adam, additional, Jilg, Stefanie, additional, Jost, Philipp J., additional, Klieser, Eckhard, additional, Steiger, Katja, additional, Magnes, Teresa, additional, Pleyer, Lisa, additional, Greil‐Ressler, Sigrun, additional, Rass, Christof, additional, Greil, Richard, additional, and Egle, Alexander, additional

Published
2019
Full Text
View/download PDF

17. Pharmacokinetics of liposomal curcumin (Lipocurc™) infusion: effect of co-medication in cancer patients and comparison with healthy individuals

Author

Bolger, Gordon T., primary, Licollari, Albert, additional, Tan, Amin, additional, Greil, Richard, additional, Vcelar, Brigitta, additional, Greil-Ressler, Sigrun, additional, Weiss, Lukas, additional, Schönlieb, Charlotte, additional, Magnes, Teresa, additional, Radl, Bianca, additional, Majeed, Muhammed, additional, and Sordillo, Peter P., additional

Published
2018
Full Text
View/download PDF

19. Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy

Author

Magnes, Teresa, primary, Melchardt, Thomas, additional, Weiss, Lukas, additional, Mittermair, Christof, additional, Neureiter, Daniel, additional, Klieser, Eckhard, additional, Gampenrieder, Simon, additional, Moser, Gerhard, additional, Gaggl, Alexander, additional, Greil, Richard, additional, and Egle, Alexander, additional

Published
2017
Full Text
View/download PDF

21. The fibrinogen/CRP ratio as a novel prognostic parameter for pancreatic cancer patients.

Author

Winder, Thomas, primary, Stotz, Michael, additional, Siebenhuener, Alexander Rheinhard, additional, Schlick, Konstantin, additional, Magnes, Teresa, additional, Samaras, Panagiotis, additional, Szkandera, Joanna, additional, Clavien, Pierre-Alain, additional, Neureiter, Daniel, additional, Greil, Richard, additional, Pestalozzi, Bernhard C., additional, Gerger, Armin, additional, Egle, Alexander, additional, and Pichler, Martin, additional

Published
2016
Full Text
View/download PDF

22. Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer

Author

Huemer, Florian, primary, Melchardt, Thomas, additional, Tränkenschuh, Wolfgang, additional, Neureiter, Daniel, additional, Moser, Gerhard, additional, Magnes, Teresa, additional, Weiss, Lukas, additional, Schlattau, Alexander, additional, Hufnagl, Clemens, additional, Ricken, Gerda, additional, Höftberger, Romana, additional, Greil, Richard, additional, and Egle, Alexander, additional

Published
2015
Full Text
View/download PDF

23. A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer.

Author

Greil, Richard, Greil-Ressler, Sigrun, Weiss, Lukas, Schönlieb, Charlotte, Magnes, Teresa, Radl, Bianca, Bolger, Gordon T., Vcelar, Brigitta, and Sordillo, Peter P.

Subjects
CURCUMIN, MEDICATION safety, METASTASIS, DRUG tolerance, PHARMACOKINETICS, PATIENTS
Abstract

Purpose: This study was conducted to investigate the safety and tolerability of increasing doses of liposomal curcumin in patients with metastatic cancer. Investigations of anti-tumor activity and of the pharmacokinetics of curcumin were secondary objectives.Methods: In this phase I, single-center, open-label study in patients with metastatic tumors, liposomal curcumin was administered as a weekly intravenous infusion for 8 weeks. Dose escalation was started at 100 mg/m2 over 8 h and the dose increased to 300 mg/m2 over 6 h.Results: 32 patients were treated. No dose-limiting toxicity was observed in 26 patients at doses between 100 and 300 mg/m2 over 8 h. Of six patients receiving 300 mg/m2 over 6 h, one patient developed hemolysis, and three other patients experienced hemoglobin decreases > 2 g/dL without signs of hemolysis. Pharmacokinetic analyses revealed stable curcumin plasma concentrations during infusion followed by rapid declines to undetectable levels after the infusion. Anti-tumor activity by RECIST V1.1 was not detected. Significant tumor marker responses and transient clinical benefit were observed in two patients.Conclusion: 300 mg/m2 liposomal curcumin over 6 h was the maximum tolerated dose in these heavily pretreated patients, and is the recommended starting dose for anti-cancer trials. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

24. CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer

Author

Melchardt, Thomas, primary, Hufnagl, Clemens, additional, Magnes, Teresa, additional, Weiss, Lukas, additional, Hutarew, Georg, additional, Neureiter, Daniel, additional, Schlattau, Alexander, additional, Moser, Gerhard, additional, Gaggl, Alexander, additional, Tränkenschuh, Wolfgang, additional, Greil, Richard, additional, and Egle, Alexander, additional

Published
2015
Full Text
View/download PDF

25. A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β2-microglobulin

Author

Melchardt, Thomas, primary, Troppan, Katharina, additional, Weiss, Lukas, additional, Hufnagl, Clemens, additional, Neureiter, Daniel, additional, Tränkenschuh, Wolfgang, additional, Hopfinger, Georg, additional, Magnes, Teresa, additional, Deutsch, Alexander, additional, Neumeister, Peter, additional, Hackl, Hubert, additional, Greil, Richard, additional, Pichler, Martin, additional, and Egle, Alexander, additional

Published
2014
Full Text
View/download PDF

27. A modified scoring of the NCCN- IPI is more accurate in the elderly and is improved by albumin and β2-microglobulin.

Author

Melchardt, Thomas, Troppan, Katharina, Weiss, Lukas, Hufnagl, Clemens, Neureiter, Daniel, Tränkenschuh, Wolfgang, Hopfinger, Georg, Magnes, Teresa, Deutsch, Alexander, Neumeister, Peter, Hackl, Hubert, Greil, Richard, Pichler, Martin, and Egle, Alexander

Subjects
LACTATE dehydrogenase, RITUXIMAB, ALBUMINS, MICROGLOBULINS, COHORT analysis, THERAPEUTICS
Abstract

The International Prognostic Index ( IPI) has been used for decades in diffuse large B-cell lymphoma ( DLBCL). A retrospective cancer registry analysis in North America showed significantly improved results when an enhanced IPI, the National Comprehensive Cancer Network ( NCCN)- IPI was applied. This novel score puts more weight on age and high levels of lactate dehydrogenase ( LDH). Nevertheless, it remains unclear if these results can be extrapolated to the general population. This retrospective bi-centre analysis included 499 unselected DLBCL patients who were treated with rituximab and anthracycline-based chemoimmunotherapy between 2004 and 2013. In our cohort, the NCCN- IPI was more accurate in identifying patients at low or high risk, despite older age, and more patients with increased LDH. Nevertheless, a modified scoring of the risk factors was required to more accurately identify elderly patients with a very favourable diagnosis, suggesting an impaired value of the original NCCN- IPI in the elderly. Serum β2-microglobulin and albumin were retained as independent prognostic factors for survival in a multivariate analysis. Our data confirm, for the first time, the superior prognostic power of the NCCN- IPI in an unselected, middle-European cohort. We furthermore propose a modified NCCN- IPI for more accurate prognostication in the elderly. Albumin and β2-microglobulin levels are likely to add significant information to the NCCN- IPI. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

28. C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling Overall Survival Prediction in Pancreatic Cancer Patients.

Author

Schlick, Konstantin, Magnes, Teresa, Huemer, Florian, Ratzinger, Lukas, Weiss, Lukas, Pichler, Martin, Melchardt, Thomas, Greil, Richard, and Egle, Alexander

Subjects
*PANCREATIC cancer, *C-reactive protein, *CANCER patients, *LYMPHOCYTES, *PANCREATIC tumors, *TUMOR markers
Abstract

Background: Despite modern chemotherapy regimens, survival of patients with locally advanced/metastatic pancreatic cancer remains dismal. Long-term survivors are rare and there are no prognostic scores to identify patients benefitting most from chemotherapy. Methods: This retrospective study includes 240 patients with pancreatic cancer who were treated in a primary palliative setting between the years 2007 to 2016 in a single academic institution. Survival rates were analyzed using the Kaplan–Meier method. Prognostic models including laboratory and clinical parameters were calculated using Cox proportional models in univariate and multivariate analyses. Results: Median age at diagnosis was 67 years (range 29–90 years), 52% were female and a majority had an ECOG performance status of 0 or 1. Locally advanced pancreatic cancer was diagnosed in 23.3% (n = 56) and primary metastatic disease in 76.7% (n = 184) of all patients. Median overall survival of the whole study cohort was 8.3 months. Investigating potential risk factors like patient characteristics, tumor marker or inflammatory markers, multivariate survival analysis found CRP (c-reactive protein) and NLR (neutrophil to lymphocyte ratio) elevation before the start of palliative chemotherapy to be independent negative prognostic factors for OS (overall survival) (p < 0.001 and p < 0.01). Grouping patients with no risk factor versus patients with one or two of the above mentioned two risk factors, we found a median OS of 16.8 months and 9.4 months (p < 0.001) respectively. By combining these two factors, we were also able to identify pancreatic cancer patients that were more likely to receive any post first line therapy. These two risk factors are predictive for improved survival independent of disease stage (III or IV) and applied chemotherapy agents in first line. Conclusion: By combining these two factors, CRP and NLR, to create a score for OS, we propose a simple, new prognostic tool for OS prediction in pancreatic cancer. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

29. Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients.

Author

Schlick K, Hohla F, Hamacher F, Hackl H, Hufnagl C, Markus S, Magnes T, Gampenrieder SP, Melchardt T, Stättner S, Hauser-Kronberger C, Greil R, and Rinnerthaler G

Abstract

FOLFIRINOX is superior to gemcitabine in patients with pancreatic cancer, but this regimen is associated with toxicity and biomarkers for response are warranted. MicroRNAs can mediate drug resistance and could provide predictive information. Altered expressions of several microRNAs including miR-21-5p, miR-10b-5p and miR-34a-5p have been previously linked to a worse response to gemcitabine. We investigated the influence of expression levels in tumor tissue of those three microRNAs on outcome to FOLFIRINOX. Twenty-nine patients with sufficient formalin-fixed paraffin-embedded tumor tissue were identified. There was no significant association between high and low expression groups for these three microRNA. We conclude that polychemotherapy combination can overcome intrinsic negative prognostic factors., Competing Interests: Financial & competing interests disclosure This research was funded by the Reiner-Brettenthaler grant 2013 from the Medical Association of Salzburg. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript., (© 2020 Konstantin Schlick.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results